192 related articles for article (PubMed ID: 33441730)
1. Molecular pathogenesis of rhegmatogenous retinal detachment.
Öhman T; Gawriyski L; Miettinen S; Varjosalo M; Loukovaara S
Sci Rep; 2021 Jan; 11(1):966. PubMed ID: 33441730
[TBL] [Abstract][Full Text] [Related]
2. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
3. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
4. Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy.
Velez G; Yang J; Li AS; Tsang SH; Bassuk AG; Mahajan VB
Sci Rep; 2019 May; 9(1):7608. PubMed ID: 31110225
[TBL] [Abstract][Full Text] [Related]
5. High subretinal fluid procoagulant activity in rhegmatogenous retinal detachment.
Ricker LJ; Dieri RA; Beckers GJ; Pels E; Liem AT; Hendrikse F; Kijlstra A; Hemker HC; La Heij EC
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5234-9. PubMed ID: 20435588
[TBL] [Abstract][Full Text] [Related]
6. Vitreous levels of Lipocalin-2 on patients with primary rhegmatogenous retinal detachment.
Batsos G; Christodoulou E; Vartholomatos G; Galanis P; Stefaniotou M
PLoS One; 2019; 14(12):e0227266. PubMed ID: 31891637
[TBL] [Abstract][Full Text] [Related]
7. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment.
Ogata N; Tombran-Tink J; Nishikawa M; Nishimura T; Mitsuma Y; Sakamoto T; Matsumura M
Am J Ophthalmol; 2001 Sep; 132(3):378-82. PubMed ID: 11530051
[TBL] [Abstract][Full Text] [Related]
8. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
9. [Multimodal Approaches for the Analysis of Retinal Functional Disorders―Focusing on Retinal Detachment].
Terasaki H
Nippon Ganka Gakkai Zasshi; 2017 Mar; 121(3):185-231. PubMed ID: 30088405
[TBL] [Abstract][Full Text] [Related]
10. Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Kaarniranta K; Resch MD
BMC Ophthalmol; 2020 Dec; 20(1):491. PubMed ID: 33371882
[TBL] [Abstract][Full Text] [Related]
11. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis.
Yu J; Peng R; Chen H; Cui C; Ba J
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8146-53. PubMed ID: 23139279
[TBL] [Abstract][Full Text] [Related]
13. Increased nitric oxide (NO) pathway metabolites in the vitreous fluid of patients with rhegmatogenous retinal detachment or diabetic traction retinal detachment.
Diederen RM; La Heij EC; Deutz NE; Kessels AG; van Eijk HM; Hendrikse F
Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):683-8. PubMed ID: 16267670
[TBL] [Abstract][Full Text] [Related]
14. Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.
Mulder VC; Bastiaans J; van Leuven CJM; van Meurs JC; Kluft C
Ophthalmologica; 2018; 240(1):23-28. PubMed ID: 29617690
[TBL] [Abstract][Full Text] [Related]
15. Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis.
Li M; Li H; Jiang P; Liu X; Xu D; Wang F
Mol Biosyst; 2014 May; 10(5):1055-62. PubMed ID: 24556753
[TBL] [Abstract][Full Text] [Related]
16. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 2000 May; 129(5):678-80. PubMed ID: 10844070
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration.
Oberstein SY; Byun J; Herrera D; Chapin EA; Fisher SK; Lewis GP
Mol Vis; 2011; 17():1794-805. PubMed ID: 21750605
[TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
20. iTRAQ Quantitative Proteomic Analysis of Vitreous from Patients with Retinal Detachment.
Santos FM; Gaspar LM; Ciordia S; Rocha AS; Castro E Sousa JP; Paradela A; Passarinha LA; Tomaz CT
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
